Table1.

Summary of immunotherapeutic options and their respective targets

Immunotherapeutic agent	Target
Recombinant BCG (rBCG)
Th1 cytokine secreting	IL-2, IL-12, IL-18, INF-α, INF-γ
BCG subcomponent	Mycobacterium cell wall extract
Non-BCG subcomponent	Pertussus S1P1
Monoclonal antibodies
Tumor associated antigens (TAAs)	β-hCG
Checkpoint inhibitors	CTLA-4, PD-L1
Vaccines
AdHER2/neu dendritic cell vaccine	HER2/neu
Cancer testis antigens (CTAs)	NY-ESO-1, recMAGE-A3
PANVAC	MUC-1, CEA, T cell costimulatory molecules
Adoptive T cell therapy
Tumor infiltrating lymphocytes (TILs)	CTAs (NY-ESO-1)
Chimeric antigen receptor (CAR)	TAAs